

**Table: Sensitivity/Specificity of Commercial Two-Tier
Testing for Lyme Disease**

<u>Study/Year</u>	<u>Sensitivity</u>	<u>Specificity</u>
Schmitz et al, 1993	66%	100%
Engstrom et al, 1995	55%	96%
Ledue et al, 1996	50%	100%
Bakken et al. 1997	75%	81%
Trevejo et al, 1999	29%	100%
Nowakowski et al, 2001	66%	99%
Bacon et al, 2003	68%	99%
Coulter et al, 2005	18%	-
Wormser et al, 2008	14.1%	-
MEAN TOTAL	49.01%	96%

1. Schmitz et al. Eur J Clin Microbiol Infect Dis. 1993;12:419-24
2. Engstrom et al. J Clin Microbiol. 1995;33:419-27.
3. Ledue et al. J Clin Microbiol. 1996;34:2343-50.
4. Bakken et al. J Clin Microbiol 1997; 35(3): 537-543.
5. Trevejo et al. J Infect Dis. 1999;179:931-8.
6. Nowakowski et al. Clin Infect Dis. 2001;33:2023-7.
7. Bacon et al. J Infect Dis. 2003;187:1187-99.
8. Coulter et al. ., J Clin Microbiol 2005; 43: 5080-5084.
9. Wormser et al. Clin Vaccine Immunol. 2008;(10):1519-22.